IntraDose: MATX began an open-label Phase II trial

End points include tumor response, tumor necrosis, pattern of progression, time

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE